TY - JOUR
T1 - Management of chronic refractory cough in adults
AU - Visca, Dina
AU - Beghè, Bianca
AU - Fabbri, Leonardo Michele
AU - Papi, Alberto
AU - Spanevello, Antonio
N1 - Funding Information:
Editorial support (in the form of critically reviewing the content written by the authors, and editing for grammar and journal style) was provided by David Young of Young Medical Communications and Consulting Ltd.
Publisher Copyright:
© 2020 European Federation of Internal Medicine
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/11
Y1 - 2020/11
N2 - Cough is a common respiratory symptom that is considered to be chronic when it lasts more than eight weeks. When severe, chronic cough may significantly impact an individual's quality of life, and such patients are frequently referred for specialist evaluation. Current international guidelines provide algorithms for the management of chronic cough: in most cases, treatment of the underlying disease is sufficient to improve or resolve cough symptoms. Severe chronic cough may significantly affect patients' quality of life and necessitate frequent referral for specialist evaluations. In this narrative review, we summarize non-pharmacologic and pharmacologic management of adult patients with chronic cough of known cause that persists after proper treatment (chronic refractory cough, CRC) or chronic cough of unknown cause in adult patients. If chronic cough persists even after treatment of the underlying disease, or if the chronic cough is not attributable to any cause, then a symptomatic approach with neuromodulators may be considered, with gabapentin as the first choice, and opioids or macrolides as alternatives. Speech pathology treatment and/or neuromodulators should be discussed with patients and alternative options carefully considered, taking into account risk/benefit. Novel promising drugs are under investigation (e.g. P2×3 inhibitors), but additional studies are needed in this field. Speech pathology can be combined with a neuromodulator to give an enhanced treatment response of longer duration suggesting that non-pharmacologic treatment may play a key role in the management of CRC.
AB - Cough is a common respiratory symptom that is considered to be chronic when it lasts more than eight weeks. When severe, chronic cough may significantly impact an individual's quality of life, and such patients are frequently referred for specialist evaluation. Current international guidelines provide algorithms for the management of chronic cough: in most cases, treatment of the underlying disease is sufficient to improve or resolve cough symptoms. Severe chronic cough may significantly affect patients' quality of life and necessitate frequent referral for specialist evaluations. In this narrative review, we summarize non-pharmacologic and pharmacologic management of adult patients with chronic cough of known cause that persists after proper treatment (chronic refractory cough, CRC) or chronic cough of unknown cause in adult patients. If chronic cough persists even after treatment of the underlying disease, or if the chronic cough is not attributable to any cause, then a symptomatic approach with neuromodulators may be considered, with gabapentin as the first choice, and opioids or macrolides as alternatives. Speech pathology treatment and/or neuromodulators should be discussed with patients and alternative options carefully considered, taking into account risk/benefit. Novel promising drugs are under investigation (e.g. P2×3 inhibitors), but additional studies are needed in this field. Speech pathology can be combined with a neuromodulator to give an enhanced treatment response of longer duration suggesting that non-pharmacologic treatment may play a key role in the management of CRC.
KW - Asthma
KW - Chronic rhinosinusitis
KW - Eosinophilic bronchitis
KW - Gastroesophageal reflux
KW - Smoking
UR - http://www.scopus.com/inward/record.url?scp=85091226848&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85091226848&partnerID=8YFLogxK
U2 - 10.1016/j.ejim.2020.09.008
DO - 10.1016/j.ejim.2020.09.008
M3 - Review article
C2 - 32958373
AN - SCOPUS:85091226848
VL - 81
JO - European Journal of Internal Medicine
JF - European Journal of Internal Medicine
SN - 0953-6205
M1 - 4616
ER -